Daniel R. Sieck

Dan concentrates his practice in the areas of mergers and acquisitions, venture capital, private equity, securities, technology law (including distributed ledger technology), and general corporate matters.

Dan regularly represents public and private companies and equity funds in stock and asset acquisitions and dispositions, mergers, joint venture, and strategic alliances. He also represents venture capitalists, emerging companies and entrepreneurs in private placements, venture capital, and other capital-raising transactions.

In addition to his transaction-based practice, Dan has served as outside general counsel to emerging companies in the life sciences, software and technology spaces, regularly providing advice on early-stage formation and strategy, corporate governance matters, federal and state securities law compliance, fiduciary obligations of directors and officers, and various day-to-day challenges and opportunities.

Dan is a member of the firm’s Emerging Companies Group steering committee and he regularly speaks and writes on topics of interest to emerging companies and investors. In addition, as a member of the Cleantech Committee of the MIT Enterprise Forum, he has organized events on a variety of topics in the clean technology industry.

Mergers and Acquisitions

• Represented a venture-backed software company in the clinical trial data management space through multiple rounds of venture financings, and in connection with the sale of the company to a London Stock Exchange listed company.
• Represented a founder owned-and-operated car wash system manufacturer in its sale to a NYSE-listed industrial manufacturing conglomerate.
• Represented a leading provider of enterprise software in its acquisitions of multiple complementary businesses.
• Represented one of the largest international manufacturers of semiconductors and electronics in several strategic acquisitions of other complementary businesses.
• Counseled to a leading integrated producer of pork products in its acquisition of the assets of a privately held competitor.
• Represented an international telecommunications company in the sale of one of its U.S. subsidiaries to a privately-held telecommunications provider.
• Represented a cloud services and software company in its sale to an NYSE-listed technology company.
• Represented a provider of K-12 education content and data management solutions in multiple acquisitions and debt and preferred stock financings and in its sale of a majority interest via merger to an affiliate of a private equity fund.
• Counseled a private equity sponsor in its acquisition of a SaaS business in the technology and telecom expense management and mobility managed services business from its founders.

Venture Capital Representation (Fund and Corporate Venture Capital)

• Represented a NYSE-listed automaker in connection with its minority investment in an autonomous driving startup.

• Counseled funds and strategic investor groups, as well as operating companies, in completing leveraged buyouts, venture capital investments, management buyouts, recapitalizations, mergers, and asset and stock acquisitions.
• Represented a UK-based venture fund in connection with its investment in several emerging technology companies and the subsequent divesture of those assets.
• Advised a venture capital fund in its investments in biotechnology and computer hardware and software technology companies.
• Represented an early-stage venture capital firm in its investment in multiple software companies.
• Represented a private investment fund in connection with its Series A and Series B co-led investments in a professional lacrosse league.

Venture-Backed Growth Companies

• Represented an emerging biotechnology company formed in the Cayman Islands, with subsidiaries in the U.S. and China, in connection with multiple debt and equity financings led by a group of international venture funds and in connection with general corporate matters.
• Represented a medical device company in the ophthalmology space in connection with bridge note financings and issuances of Series C through E preferred stock.
• Represented numerous biotechnology and software companies in connection with their corporate formation, seed and venture financings and general corporate matters.
• Represented a late-stage emerging company in connection with its growth equity financing.
• Outside general counsel to a drug discovery company; advise on a wide variety of issues including financings, licensing, employment, benefits, and intellectual property.

• Boston Magazine, Top Lawyers List, Corporate Law (2021-2023)
• Legal 500 United States: M&A/Corporate and Commercial: Venture Capital and Emerging Companies (2025)